Crossmark

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes

Crossref DOI link: https://doi.org/10.1007/s11154-021-09699-1

Published Online: 2022-01-07

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahapatra, Manoj Kumar https://orcid.org/0000-0001-8147-5283
Karuppasamy, Muthukumar https://orcid.org/0000-0003-0034-9950
Sahoo, Biswa Mohan https://orcid.org/0000-0001-8822-0427
License Information

Text and Data Mining valid from 2022-01-07

Version of Record valid from 2022-01-07
More Information

Article History

Accepted: 27 November 2021

First Online: 7 January 2022

Declarations

:

: Authors declare no conflicts of interest.